Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections The GOLD Randomized Clinical Trial

被引:521
|
作者
Lind, Marcus [1 ,2 ]
Polonsky, William [3 ]
Hirsch, Irl B. [4 ]
Heise, Tim [5 ]
Bolinder, Jan [6 ]
Dahlqvist, Sofia [2 ]
Schwarz, Erik [7 ]
Olafsdottir, Arndis Finna [2 ]
Frid, Anders [8 ,9 ]
Wedel, Hans [10 ]
Ahlen, Elsa [1 ,2 ]
Nystrom, Thomas [11 ]
Hellman, Jarl [12 ]
机构
[1] Univ Gothenburg, Dept Mol & Clin Med, Gothenburg, Sweden
[2] NU Hosp Grp, Dept Med, Uddevalla, Sweden
[3] Univ Calif San Diego, La Jolla, CA 92093 USA
[4] Univ Washington, Sch Med, Seattle, WA USA
[5] Profil, Neuss, Germany
[6] Karolinska Univ Hosp Huddinge, Karolinska Inst, Dept Med, Stockholm, Sweden
[7] Univ Orebro, Fac Med & Hlth, Dept Internal Med, Orebro, Sweden
[8] Skane Univ Hosp, Dept Clin Sci, Div Endocrinol, Malmo, Sweden
[9] Lund Univ, Lund, Sweden
[10] Univ Gothenburg, Hlth Metr Sahlgrenska Acad, Gothenburg, Sweden
[11] Karolinska Inst, Sodersjukhuset, Dept Clin Sci & Educ, Stockholm, Sweden
[12] Uppsala Univ, Dept Med Sci Clin Diabet & Metab, Uppsala, Sweden
来源
关键词
BLOOD-GLUCOSE; TREATMENT SATISFACTION; SEVERE HYPOGLYCEMIA; SWEDISH VERSION; PUMP THERAPY; ASSOCIATION; REDUCTION; FREQUENCY;
D O I
10.1001/jama.2016.19976
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE The majority of individuals with type 1 diabetes do not meet recommended glycemic targets. OBJECTIVE To evaluate the effects of continuous glucose monitoring in adults with type 1 diabetes treated with multiple daily insulin injections. DESIGN, SETTING, AND PARTICIPANTS Open-label crossover randomized clinical trial conducted in 15 diabetes outpatient clinics in Sweden between February 24, 2014, and June 1, 2016 that included 161 individuals with type 1 diabetes and hemoglobin A(1c) (HbA(1c)) of at least 7.5%(58 mmol/mol) treated with multiple daily insulin injections. INTERVENTIONS Participants were randomized to receive treatment using a continuous glucose monitoring system or conventional treatment for 26 weeks, separated by a washout period of 17 weeks. MAIN OUTCOMES AND MEASURES Difference in HbA(1c) between weeks 26 and 69 for the 2 treatments. Adverse events including severe hypoglycemia were also studied. RESULTS Among 161 randomized participants, mean age was 43.7 years, 45.3% were women, and mean HbA(1c) was 8.6%(70 mmol/mol). A total of 142 participants had follow-up data in both treatment periods. Mean HbA(1c) was 7.92%(63 mmol/mol) during continuous glucose monitoring use and 8.35%(68 mmol/mol) during conventional treatment (mean difference, -0.43% [95% CI, -0.57% to -0.29%] or -4.7 [-6.3 to -3.1 mmol/mol]; P < .001). Of 19 secondary end points comprising psychosocial and various glycemic measures, 6 met the hierarchical testing criteria of statistical significance, favoring continuous glucose monitoring compared with conventional treatment. Five patients in the conventional treatment group and 1 patient in the continuous glucose monitoring group had severe hypoglycemia. During washout when patients used conventional therapy, 7 patients had severe hypoglycemia. CONCLUSIONS AND RELEVANCE Among patients with inadequately controlled type 1 diabetes treated with multiple daily insulin injections, the use of continuous glucose monitoring compared with conventional treatment for 26 weeks resulted in lower HbA(1c). Further research is needed to assess clinical outcomes and longer-term adverse effects.
引用
收藏
页码:379 / 387
页数:9
相关论文
共 50 条
  • [1] Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections (vol 317, pg 379, 2017)
    Lind, M.
    Polonsky, W.
    Hirsch, I. B.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (18): : 1912 - 1912
  • [2] Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections The DIAMOND Randomized Clinical Trial
    Beck, Roy W.
    Riddlesworth, Tonya
    Ruedy, Katrina
    Ahmann, Andrew
    Bergenstal, Richard
    Haller, Stacie
    Kollman, Craig
    Kruger, Davida
    McGill, Janet B.
    Polonsky, William
    Toschi, Elena
    Wolpert, Howard
    Price, David
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (04): : 371 - 378
  • [3] Effect of Continuous Glucose Monitoring on Glycemic Control in Adults Using Multiple Daily Insulin Injections
    Price, David A.
    Riddlesworth, Tonya
    Beck, Roy W.
    Wolpert, Howard A.
    Bergenstal, Richard M.
    Ahmann, Andrew J.
    DIABETES, 2017, 66 : A17 - A17
  • [4] A Randomized Clinical Trial of the Effect of Continuous Glucose Monitoring on Nocturnal Hypoglycemia, Daytime Hypoglycemia, Glycemic Variability, and Hypoglycemia Confidence in Persons with Type 1 Diabetes Treated with Multiple Daily Insulin Injections (GOLD-3)
    Olafsdottir, Arndis F.
    Polonsky, William
    Bolinder, Jan
    Hirsch, Irl B.
    Dahlqvist, Sofia
    Wedel, Hans
    Nystrom, Thomas
    Wijkman, Magnus
    Schwarcz, Erik
    Hellman, Jarl
    Heise, Tim
    Lind, Marcus
    DIABETES TECHNOLOGY & THERAPEUTICS, 2018, 20 (04) : 274 - 284
  • [5] Effect of Continuous Glucose Monitoring on Glycemic Control in Patients With Type 2 Diabetes Treated With Basal Insulin A Randomized Clinical Trial
    Martens, Thomas
    Beck, Roy W.
    Bailey, Ryan
    Ruedy, Katrina J.
    Calhoun, Peter
    Peters, Anne L.
    Pop-Busui, Rodica
    Philis-Tsimikas, Athena
    Bao, Shichun
    Umpierrez, Guillermo
    Davis, Georgia
    Kruger, Davida
    Bhargava, Anuj
    Young, Laura
    McGill, Janet B.
    Aleppo, Grazia
    Nguyen, Quang T.
    Orozco, Ian
    Biggs, William
    Lucas, K. Jean
    Polonsky, William H.
    Buse, John B.
    Price, David
    Bergenstal, Richard M.
    Group, Mobile Study
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2021, 325 (22): : 2262 - 2272
  • [6] Intermittently Scanned Continuous Glucose Monitoring and Automated Bolus Calculation in Type 1 Diabetes Treated with Multiple Daily Insulin Injections: A Randomized Controlled Trial
    Secher, Anna L.
    Pedersen-Bjergaard, Ulrik
    Svendsen, Ole L.
    Gade-Rasmussen, Birthe
    Almdal, Thomas P.
    Raimond, Linda H.
    Vistisen, Dorte
    Norgaard, Kirsten
    DIABETES, 2021, 70
  • [7] Effect of Continuous Glucose Monitoring on Glycemic Control in Adolescents and Young Adults With Type 1 Diabetes A Randomized Clinical Trial
    Laffel, Lori M.
    Kanapka, Lauren G.
    Beck, Roy W.
    Bergamo, Katherine
    Clements, Mark A.
    Criego, Amy
    DeSalvo, Daniel J.
    Goland, Robin
    Hood, Korey
    Liljenquist, David
    Messer, Laurel H.
    Monzavi, Roshanak
    Mouse, Thomas J.
    Prahalad, Priya
    Sherr, Jennifer
    Simmons, Jill H.
    Wadwa, R. Paul
    Weinstock, Ruth S.
    Willi, Steven M.
    Miller, Kellee M.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (23): : 2388 - 2396
  • [8] Characteristics of Continuous Glucose Monitoring Metrics in Persons with Type 1 and Type 2 Diabetes Treated with Multiple Daily Insulin Injections
    Hallstrom, Sara
    Hirsch, Irl B.
    Ekelund, Magnus
    Sofizadeh, Sheyda
    Albrektsson, Henrik
    Dahlqvist, Solveig
    Svensson, Ann-Marie
    Lind, Marcus
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 (06) : 425 - 433
  • [9] Impact of continuous glucose monitoring (CGM) on hypoglycaemia in type 1 diabetes adults on multiple daily insulin injections (MDI)
    Olafsdottir, A. F.
    Polonsky, W.
    Bolinder, J.
    Hirsch, I. B.
    Heise, T.
    Wedel, H.
    Dahlqvist, S.
    Lind, M.
    DIABETOLOGIA, 2017, 60 : S328 - S328
  • [10] The majority of people with type 1 diabetes and multiple daily insulin injections benefit from using continuous glucose monitoring: An analysis based on the GOLD randomized trial (GOLD-5)
    Olafsdottir, Arndis F.
    Bolinder, Jan
    Heise, Tim
    Polonsky, William
    Ekelund, Magnus
    Wijkman, Magnus
    Pivodic, Aldina
    Ahlen, Elsa
    Schwarcz, Erik
    Nystrom, Thomas
    Hellman, Jarl
    Hirsch, Irl B.
    Lind, Marcus
    DIABETES OBESITY & METABOLISM, 2021, 23 (02): : 619 - 630